The follow-up plan, with its rationale and safety-net instructions, allows the result to be acted on consistently over time
Burstein, S., Grumbach, M
The Phase 2 trial data confirms this: the 1mg dose group achieved only 8.7% weight loss at 48 weeks, indicating that low doses produce modest effects that accumulate slowly
Evidence supporting the idea that vessel normalization can improve cancer therapy has been obtained in mouse models
The doses chosen were because higher doses of cagrilintide may be associated with gastrointestinal adverse effects, in particular nausea and vomiting, and require dose escalation to be attained
Understanding this relationship helps ensure timely medical care and better long-term health outcomes